At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Merus regains some lost pride while Bicycle rides to even greater heights.
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.